• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SER-109（一种纯化的研究性微生物组疗法）的制造过程降低了冠状病毒从供体粪便传播的风险。

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.

作者信息

McChalicher Christopher, Abdulaziz Ahmad, Zhou S Steve, Lombardo Mary-Jane, Hasson Brooke, Auniņš John G, McGovern Barbara H, Ege David S

机构信息

Seres Therapeutics, Cambridge, Massachusetts, USA.

Microbac Laboratories, Inc, Sterling, Virginia, USA.

出版信息

Open Forum Infect Dis. 2022 Sep 2;9(9):ofac448. doi: 10.1093/ofid/ofac448. eCollection 2022 Sep.

DOI:10.1093/ofid/ofac448
PMID:36158136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9492665/
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.

摘要

当缺乏适当的生产控制和灭活工艺时，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）可能会给接受供体来源微生物组疗法治疗的患者带来风险。我们报告称，SER-109是一种为降低复发风险而研发的纯化研究性微生物组疗法，其生产步骤可灭活猪流行性腹泻病毒，这是SARS-CoV-2的一种模型冠状病毒。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9657/9492665/b302d41a5744/ofac448f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9657/9492665/b302d41a5744/ofac448f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9657/9492665/b302d41a5744/ofac448f1.jpg

相似文献

1
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool.SER-109（一种纯化的研究性微生物组疗法）的制造过程降低了冠状病毒从供体粪便传播的风险。
Open Forum Infect Dis. 2022 Sep 2;9(9):ofac448. doi: 10.1093/ofid/ofac448. eCollection 2022 Sep.
2
SER-109, an Oral Microbiome Therapy for Recurrent Infection.SER-109，一种用于复发性感染的口腔微生物组疗法。
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
3
[Reconsidering the technical aspects and quality management background of faecal microbiota transplantation due to the novel coronavirus pandemic].[鉴于新型冠状病毒大流行重新审视粪便微生物群移植的技术方面和质量管理背景]
Orv Hetil. 2020 Nov 1;161(44):1858-1871. doi: 10.1556/650.2020.32023.
4
[Fecal microbiota transplantation: indications, risks and opportunities].[粪便微生物群移植：适应症、风险与机遇]
Inn Med (Heidelb). 2022 Oct;63(10):1036-1042. doi: 10.1007/s00108-022-01399-5. Epub 2022 Sep 2.
5
Faecal microbiota transplantation for infection: Four years' experience of the Netherlands Donor Feces Bank.粪便微生物群移植治疗 感染：荷兰供体粪便银行四年经验。
United European Gastroenterol J. 2020 Dec;8(10):1236-1247. doi: 10.1177/2050640620957765. Epub 2020 Sep 29.
6
Modeling Donor Screening Strategies to Reduce the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission via Fecal Microbiota Transplantation.模拟供体筛查策略以降低严重急性呼吸综合征冠状病毒2通过粪便微生物群移植传播的风险
Open Forum Infect Dis. 2020 Oct 19;7(11):ofaa499. doi: 10.1093/ofid/ofaa499. eCollection 2020 Nov.
7
How to prepare stool banks for an appropriate response to the ongoing COVID-19 pandemic: Experiences in the Netherlands and a retrospective comparative cohort study for faecal microbiota transplantation.如何为应对持续的 COVID-19 大流行做好粪便库的准备：荷兰的经验以及粪菌移植的回顾性对照队列研究。
PLoS One. 2022 Mar 17;17(3):e0265426. doi: 10.1371/journal.pone.0265426. eCollection 2022.
8
COVID-19 and coinfection with Clostridioides (Clostridium) difficile in an infant with gastrointestinal manifestation.一名有胃肠道表现的婴儿感染新冠病毒并合并艰难梭菌感染
Einstein (Sao Paulo). 2020 Dec 7;18:eRC6048. doi: 10.31744/einstein_journal/2020RC6048. eCollection 2020.
9
Safety of fecal microbiota transplantation for infection focusing on pathobionts and SARS-CoV-2.粪便微生物群移植治疗感染的安全性，重点关注致病共生菌和严重急性呼吸综合征冠状病毒2
Therap Adv Gastroenterol. 2021 Apr 21;14:17562848211009694. doi: 10.1177/17562848211009694. eCollection 2021.
10
A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.一种新型微生物组治疗药物可增加肠道微生物多样性，预防复发性艰难梭菌感染。
J Infect Dis. 2016 Jul 15;214(2):173-81. doi: 10.1093/infdis/jiv766. Epub 2016 Feb 8.

引用本文的文献

1
What's New and What's Next in Fecal Microbiota Transplantation?粪便微生物群移植的新进展与未来方向？
Biologics. 2025 Aug 21;19:481-496. doi: 10.2147/BTT.S486372. eCollection 2025.
2
Gut Microbiota and New Microbiome-Targeted Drugs for Infections.肠道微生物群与新型针对微生物群的抗感染药物
Antibiotics (Basel). 2024 Oct 20;13(10):995. doi: 10.3390/antibiotics13100995.
3
Systematic review of the orally administered microbiome therapeutic, fecal microbiota spores, live-brpk, to prevent recurrence of infection in adults.

本文引用的文献

1
Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection.胃肠道症状和 SARS-CoV-2 RNA 的粪便脱落表明胃肠道感染时间延长。
Med. 2022 Jun 10;3(6):371-387.e9. doi: 10.1016/j.medj.2022.04.001. Epub 2022 Apr 13.
2
SER-109, an Oral Microbiome Therapy for Recurrent Infection.SER-109，一种用于复发性感染的口腔微生物组疗法。
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
3
Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients With COVID-19 Infection: A Systematic Review and Meta-analysis.
口服微生物群疗法——粪便微生物群孢子（活芽孢）预防成人感染复发的系统评价
SAGE Open Med. 2024 Oct 9;12:20503121241274192. doi: 10.1177/20503121241274192. eCollection 2024.
4
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.一种用于复发性艰难梭菌感染的微生物组疗法3期试验的综合安全性和有效性分析。
Infect Dis Ther. 2024 Oct;13(10):2105-2121. doi: 10.1007/s40121-024-01007-z. Epub 2024 Jun 28.
5
A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Infection.复发性感染的现有和研究性粪便微生物群移植产品比较
Antibiotics (Basel). 2024 May 12;13(5):436. doi: 10.3390/antibiotics13050436.
6
Microbiota-Based Live Biotherapeutic Products for Infection- The Devil is in the Details.用于感染治疗的基于微生物群的活体生物治疗产品——细节决定成败。
Infect Drug Resist. 2024 Feb 15;17:623-639. doi: 10.2147/IDR.S419243. eCollection 2024.
7
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool.经纯化的微生物组治疗制品的制造工艺降低了供体粪便中潜在细菌病原体传播的风险。
J Infect Dis. 2023 Nov 11;228(10):1452-1455. doi: 10.1093/infdis/jiad298.
8
infection: microbe-microbe interactions and live biotherapeutics.感染：微生物-微生物相互作用与活体生物治疗剂
Front Microbiol. 2023 May 9;14:1182612. doi: 10.3389/fmicb.2023.1182612. eCollection 2023.
9
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.在复发性艰难梭菌感染的成人中作为研究用微生物组治疗药物的 SER-109 的安全性和耐受性：一项 3 期、开放标签、单臂试验。
JAMA Netw Open. 2023 Feb 1;6(2):e2255758. doi: 10.1001/jamanetworkopen.2022.55758.
新型冠状病毒感染患者粪便 SARS-CoV-2 RNA 的流行和持续脱落：系统评价和荟萃分析。
Clin Transl Gastroenterol. 2021 Apr 9;12(4):e00343. doi: 10.14309/ctg.0000000000000343.
4
A method for detection of SARS-CoV-2 RNA in healthy human stool: a validation study.健康人体粪便中 SARS-CoV-2 RNA 的检测方法：一项验证研究。
Lancet Microbe. 2021 Jun;2(6):e259-e266. doi: 10.1016/S2666-5247(21)00059-8. Epub 2021 Mar 31.
5
Potential intestinal infection and faecal-oral transmission of SARS-CoV-2.新冠病毒可能存在肠道感染和粪-口传播途径。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283. doi: 10.1038/s41575-021-00416-6. Epub 2021 Feb 15.
6
Effective inactivation of porcine epidemic diarrhea virus on contaminated surgery masks by low-concentrated sodium hypochlorite dispersion.低浓度次氯酸钠分散液有效灭活污染手术口罩上的猪流行性腹泻病毒。
Pol J Vet Sci. 2020 Dec;23(4):647-650. doi: 10.24425/pjvs.2020.135801.
7
Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2.SARS-CoV-2 的潜在来源、传播方式和预防措施的有效性。
J Hosp Infect. 2020 Dec;106(4):678-697. doi: 10.1016/j.jhin.2020.09.022. Epub 2020 Sep 18.
8
Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building.高层建筑物中 SARS-CoV-2 粪便气溶胶传播的可能证据。
Ann Intern Med. 2020 Dec 15;173(12):974-980. doi: 10.7326/M20-0928. Epub 2020 Sep 1.
9
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.COVID-19 大流行期间粪便微生物群移植服务的重组。
Gut. 2020 Sep;69(9):1555-1563. doi: 10.1136/gutjnl-2020-321829. Epub 2020 Jul 3.
10
Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era.粪便微生物群移植治疗复发性艰难梭菌感染：新冠疫情时代
Am J Gastroenterol. 2020 Jul;115(7):971-974. doi: 10.14309/ajg.0000000000000689.